» Articles » PMID: 15575056

Mutation of CEBPA in Familial Acute Myeloid Leukemia

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2004 Dec 3
PMID 15575056
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

We describe a family in whom three members affected by acute myeloid leukemia (AML) had an identical, 212delC mutation in CEBPA, the gene encoding the granulocytic differentiation factor C/EBPalpha. Unaffected family members did not have this mutation. Latent periods of 10, 18, and 30 years elapsed before the onset of overt leukemia in the three patients. One of them had a second CEBPA mutation, but only at the time of diagnosis. All three patients are currently well, with no abnormalities in the bone marrow. CEBPA mutation is apparently the primary event in the development of AML in this family.

Citing Articles

Genetic predisposition to myelodysplastic syndrome: Genetic counseling and transplant implications.

Liu Y, Calzone K, McReynolds L Semin Hematol. 2024; 61(6):370-378.

PMID: 39443230 PMC: 11661499. DOI: 10.1053/j.seminhematol.2024.09.003.


Familial acute myeloid leukemia due to a novel germline CEBPA pathogenic variant - a case report.

Gava F, Catto L, Valera E, Francisco Dos Reis M, Pintao M, Chauffaille M Hematol Transfus Cell Ther. 2024; 46 Suppl 6():S417-S420.

PMID: 39278810 PMC: 11726073. DOI: 10.1016/j.htct.2024.07.004.


Molecular pathophysiology of germline mutations in acute myeloid leukemia.

Nagata Y Int J Hematol. 2024; 120(4):417-426.

PMID: 39150677 DOI: 10.1007/s12185-024-03824-x.


Germline CEBPA Mutation as a Rare Cause of Chronic Neutropenia.

Askin A, Bektas S, Serin I, Mutlu Y, Aydin B, Sevindik O Indian J Hematol Blood Transfus. 2024; 40(3):527-530.

PMID: 39011240 PMC: 11246327. DOI: 10.1007/s12288-023-01725-3.


Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Banaszak L, Cabral P, Smith-Simmer K, Hassan A, Brunner M, Fallon M JCO Precis Oncol. 2024; 8:e2300518.

PMID: 38848520 PMC: 11234342. DOI: 10.1200/PO.23.00518.